ALBO - Albireo Pharma Gets A 'Thumbs Up'

• Shares of Albireo Pharma have fallen ~30% from their post-secondary intraday highs as concerns about market potential and competition have muted any advance.
• The company’s lead asset, odevixibat, has a July 20th, 2021 PDUFA date for the treatment of PFIC, a bile acid indication with no approved therapy.
• With a high likelihood of approval, a ~$100 million priority voucher pending, and two ongoing Phase 3 trials for two other orphan bile acid indications, Albireo warranted further investigation.
• A full investment analysis follows in the paragraphs below.

For further details see: